Puma Continues Long Post-ASCO Plunge On Latest Data
This article was originally published in Scrip
Executive Summary
Puma Biotechnology Inc.'s data for the tyrosine kinase inhibitor neratinib (PB272) in the treatment of breast cancer now seem to disappoint investors every time the Los Angeles-based company reports results from its clinical trials, bringing Puma's stock to its second-lowest price of the year on Dec. 11.